Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

CDA as a predictive marker for life-threatening toxicities in patients with AML treated with cytarabine.

Fanciullino R, Farnault L, Donnette M, Imbs DC, Roche C, Venton G, Berda-Haddad Y, Ivanov V, Ciccolini J, Ouafik L, Lacarelle B, Costello R.

Blood Adv. 2018 Mar 13;2(5):462-469. doi: 10.1182/bloodadvances.2017014126. Erratum in: Blood Adv. 2018 May 8;2(9):1013.

2.

Cytidine deaminase genetic variants influence RNA expression and cytarabine cytotoxicity in acute myeloid leukemia.

Abraham A, Varatharajan S, Abbas S, Zhang W, Shaji RV, Ahmed R, Abraham A, George B, Srivastava A, Chandy M, Mathews V, Balasubramanian P.

Pharmacogenomics. 2012 Feb;13(3):269-82. doi: 10.2217/pgs.11.149.

PMID:
22304580
3.

RNA expression of genes involved in cytarabine metabolism and transport predicts cytarabine response in acute myeloid leukemia.

Abraham A, Varatharajan S, Karathedath S, Philip C, Lakshmi KM, Jayavelu AK, Mohanan E, Janet NB, Srivastava VM, Shaji RV, Zhang W, Abraham A, Viswabandya A, George B, Chandy M, Srivastava A, Mathews V, Balasubramanian P.

Pharmacogenomics. 2015 Jul;16(8):877-90. doi: 10.2217/pgs.15.44. Epub 2015 Jun 17.

4.

Association of polymorphisms of cytosine arabinoside-metabolizing enzyme gene with therapeutic efficacy for acute myeloid leukemia.

Xu PP, Chen BA, Feng JF, Cheng L, Xia GH, Li YF, Qian J, Ding JH, Lu ZH, Wang XM, Xu K, Schultz M.

Chin Med J (Engl). 2012 Jun;125(12):2137-43.

PMID:
22884143
6.

Cytidine deaminase genotype and toxicity of cytosine arabinoside therapy in children with acute myeloid leukemia.

Bhatla D, Gerbing RB, Alonzo TA, Conner H, Ross JA, Meshinchi S, Zhai X, Zamzow T, Mehta PA, Geiger H, Perentesis J, Davies SM.

Br J Haematol. 2009 Feb;144(3):388-94. doi: 10.1111/j.1365-2141.2008.07461.x. Epub 2008 Nov 22.

7.

Lethal toxicity after administration of azacytidine: implication of the cytidine deaminase-deficiency syndrome.

Fanciullino R, Mercier C, Serdjebi C, Berda Y, Fina F, Ouafik L, Lacarelle B, Ciccolini J, Costello R.

Pharmacogenet Genomics. 2015 Jun;25(6):317-21. doi: 10.1097/FPC.0000000000000139.

PMID:
25850965
8.

FFCD-1004 Clinical Trial: Impact of Cytidine Deaminase Activity on Clinical Outcome in Gemcitabine-Monotherapy Treated Patients.

Serdjebi C, Gagnière J, Desramé J, Fein F, Guimbaud R, François E, André T, Seitz JF, Montérymard C, Arsene D, Volet J, Abakar-Mahamat A, Lecomte T, Guerin-Meyer V, Legoux JL, Deplanque G, Guillet P, Ciccolini J, Lepage C, Dahan L.

PLoS One. 2015 Aug 26;10(8):e0135907. doi: 10.1371/journal.pone.0135907. eCollection 2015.

9.

Cytidine deaminase residual activity in serum is a predictive marker of early severe toxicities in adults after gemcitabine-based chemotherapies.

Ciccolini J, Dahan L, André N, Evrard A, Duluc M, Blesius A, Yang C, Giacometti S, Brunet C, Raynal C, Ortiz A, Frances N, Iliadis A, Duffaud F, Seitz JF, Mercier C.

J Clin Oncol. 2010 Jan 1;28(1):160-5. doi: 10.1200/JCO.2009.24.4491. Epub 2009 Nov 23.

PMID:
19933910
10.

The role of cytidine deaminase and GATA1 mutations in the increased cytosine arabinoside sensitivity of Down syndrome myeloblasts and leukemia cell lines.

Ge Y, Jensen TL, Stout ML, Flatley RM, Grohar PJ, Ravindranath Y, Matherly LH, Taub JW.

Cancer Res. 2004 Jan 15;64(2):728-35.

11.
12.

GATA1, cytidine deaminase, and the high cure rate of Down syndrome children with acute megakaryocytic leukemia.

Ge Y, Stout ML, Tatman DA, Jensen TL, Buck S, Thomas RL, Ravindranath Y, Matherly LH, Taub JW.

J Natl Cancer Inst. 2005 Feb 2;97(3):226-31.

PMID:
15687366
13.

SNP analyses in cytarabine metabolizing enzymes in AML patients and their impact on treatment response and patient survival: identification of CDA SNP C-451T as an independent prognostic parameter for survival.

Mahlknecht U, Dransfeld CL, Bulut N, Kramer M, Thiede C, Ehninger G, Schaich M.

Leukemia. 2009 Oct;23(10):1929-32. doi: 10.1038/leu.2009.113. Epub 2009 May 21. No abstract available.

PMID:
19458626
14.

CDA deficiency as a possible culprit for life-threatening toxicities after cytarabine plus 6-mercaptopurine therapy: pharmacogenetic investigations.

Ciccolini J, Evrard A, M'Batchi L, Pourroy B, Mercier C, Iliadis A, Lacarelle B, Verschuur A, Ouafik L, André N.

Pharmacogenomics. 2012 Mar;13(4):393-7. doi: 10.2217/pgs.11.175.

PMID:
22379997
15.

SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia.

Schneider C, Oellerich T, Baldauf HM, Schwarz SM, Thomas D, Flick R, Bohnenberger H, Kaderali L, Stegmann L, Cremer A, Martin M, Lohmeyer J, Michaelis M, Hornung V, Schliemann C, Berdel WE, Hartmann W, Wardelmann E, Comoglio F, Hansmann ML, Yakunin AF, Geisslinger G, Ströbel P, Ferreirós N, Serve H, Keppler OT, Cinatl J Jr.

Nat Med. 2017 Feb;23(2):250-255. doi: 10.1038/nm.4255. Epub 2016 Dec 19. Erratum in: Nat Med. 2017 Jun 6;23 (6):788.

PMID:
27991919
16.

Variability in transport and biotransformation of cytarabine is associated with its toxicity in peripheral blood mononuclear cells.

Parmar S, Seeringer A, Denich D, Gärtner F, Pitterle K, Syrovets T, Ohmle B, Stingl JC.

Pharmacogenomics. 2011 Apr;12(4):503-14. doi: 10.2217/pgs.10.200.

PMID:
21521023
17.

Decreased survival in normal karyotype AML with single-nucleotide polymorphisms in genes encoding the AraC metabolizing enzymes cytidine deaminase and 5'-nucleotidase.

Falk IJ, Fyrberg A, Paul E, Nahi H, Hermanson M, Rosenquist R, Höglund M, Palmqvist L, Stockelberg D, Wei Y, Gréen H, Lotfi K.

Am J Hematol. 2013 Dec;88(12):1001-6. doi: 10.1002/ajh.23549. Epub 2013 Sep 9.

18.

High-dose cytarabine as salvage therapy for relapsed or refractory acute myeloid leukemia--is more better or more of the same?

Wolach O, Itchaki G, Bar-Natan M, Yeshurun M, Ram R, Herscovici C, Shpilberg O, Douer D, Tallman MS, Raanani P.

Hematol Oncol. 2016 Mar;34(1):28-35. doi: 10.1002/hon.2191. Epub 2015 Feb 17.

PMID:
25689584
19.

Increased CDA expression/activity in males contributes to decreased cytidine analog half-life and likely contributes to worse outcomes with 5-azacytidine or decitabine therapy.

Mahfouz RZ, Jankowska A, Ebrahem Q, Gu X, Visconte V, Tabarroki A, Terse P, Covey J, Chan K, Ling Y, Engelke KJ, Sekeres MA, Tiu R, Maciejewski J, Radivoyevitch T, Saunthararajah Y.

Clin Cancer Res. 2013 Feb 15;19(4):938-48. doi: 10.1158/1078-0432.CCR-12-1722. Epub 2013 Jan 3.

20.

Purine nucleoside analogues in the treatment of myleoid leukemias.

Robak T.

Leuk Lymphoma. 2003 Mar;44(3):391-409. Review.

PMID:
12688309

Supplemental Content

Support Center